Short-Term Treatment of Catatonia With Amantadine in Schizophrenia and Schizoaffective Disorder

Lucena, David Freitas de; Pinto, José Roberto Aparecido dos Santos; Hallak, Jaime Eduardo Cecílio; Crippa, José Alexandre de Souza; Gama, Clarissa Severino

doi:10.1097/jcp.0b013e31825ebf6e

Cited by 11 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therapeutic efficiacy of the N-methyl-D-aspartate (NMDA) antagonist amantadine has been reported by Northoff et al 45 and Freitas de Lucena et al 46 Northoff et al reported three cases with acute akinetic catatonia, in which IV infusion of 500 mg amantadine (if necessary, repeated after 24 hours) led to resolution of catatonic symptoms. Considerable reduction of scores in various motor scales was seen with most pronounced effects 4–6 hours after administration.…”

Section: Resultsmentioning

confidence: 93%

Systematic review of catatonia treatment

Pelzer¹,

Heijden²,

Boer³

2018

NDT

113

View full text Add to dashboard Cite

ObjectiveTo investigate the evidence-based treatment of catatonia in adults. The secondary aim is to develop a treatment protocol.Materials and methodsA systematic review of published treatment articles (case series, cohort or randomized controlled studies) which examined the effects of particular interventions for catatonia and/or catatonic symptoms in adult populations and used valid outcome measures was performed. The articles for this review were selected by searching the electronic databases of the Cochrane Library, MEDLINE, EMBASE and PSYCHINFO.ResultsThirty-one articles met the inclusion criteria. Lorazepam and electroconvulsive therapy (ECT) proved to be the most investigated treatment interventions. The response percentages in Western studies varied between 66% and 100% for studies with lorazepam, while in Asian and Indian studies, they were 0% and 100%. For ECT, the response percentages are 59%–100%. There does not seem to be evidence for the use of antipsychotics in catatonic patients without any underlying psychotic disorder.ConclusionLorazepam and ECT are effective treatments for which clinical evidence is found in the literature. It is not possible to develop a treatment protocol because the evidence for catatonia management on the basis of the articles reviewed is limited. Stringent treatment studies on catatonia are warranted.

show abstract

Section: Resultsmentioning

confidence: 93%

Systematic review of catatonia treatment

Pelzer¹,

Heijden²,

Boer³

2018

NDT

113

View full text Add to dashboard Cite

show abstract

“…This allows us to infer that the administration of NMDA inhibitors, by modulating pyramidal CaMK2A-expressing neurons, can modify and reshape NMDA-dependent synapses in the vmPFC making them more active, nonetheless, more research needs to be done to verify this hypothesis. Catatonic patients who are not fully responsive to Benzodiazepines (BDZ) have shown positive response to treatment in combination with NMDA inhibitors such as amantadine and memantine (Babington and Spiegel, 2007 ; de Lucena et al, 2012 ; Ellul and Choucha, 2015 ). Table 2 summarizes some cases reported in the literature using amantadine in combination with other medications resulting in positive clinical outcomes.…”

Section: Pathophysiology Of Catatoniamentioning

confidence: 99%

Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence

Ariza-Salamanca

Corrales-Hernández

Pachón-Londoño

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

This review aims to describe the clinical spectrum of catatonia, in order to carefully assess the involvement of astrocytes, neurons, oligodendrocytes, and microglia, and articulate the available preclinical and clinical evidence to achieve a translational understanding of the cellular and molecular mechanisms behind this disorder. Catatonia is highly common in psychiatric and acutely ill patients, with prevalence ranging from 7.6% to 38%. It is usually present in different psychiatric conditions such as mood and psychotic disorders; it is also a consequence of folate deficiency, autoimmunity, paraneoplastic disorders, and even autistic spectrum disorders. Few therapeutic options are available due to its complexity and poorly understood physiopathology. We briefly revisit the traditional treatments used in catatonia, such as antipsychotics, electroconvulsive therapy, and benzodiazepines, before assessing novel therapeutics which aim to modulate molecular pathways through different mechanisms, including NMDA antagonism and its allosteric modulation, and anti-inflammatory drugs to modulate microglia reaction and mitigate oxidative stress, such as lithium, vitamin B12, and NMDAr positive allosteric modulators.

show abstract

“…Одним из потенциально перспективных альтернативных препаратов медикаментозного лечения кататонических расстройств, по данным исследований, являются антагонисты NMDA-рецепторов. Авторы систематических обзоров литературы, посвященных терапии кататонических расстройств [90][91][92][93][94], сообщают об эффективности применения амантадина у больных шизофренией и РШС с феноменами кататонии. Мемантин в указанных случаях применялся как в качестве монотерапии (вариабельность доз от 10 до 60 мг), так и в сочетании с бензодиазепинами.…”

Section: альтернативные методы лечения кататонииunclassified

Therapy of Catatonia in Schizophrenia and Schizophrenia Spectrum Disorders

Ivanov

Borisova

et al. 2022

Psychiatry

View full text Add to dashboard Cite

Background: the study of catatonia’s treatment methods is one of the most important researchers’ tasks, nevertheless the common therapeutic strategies of cupping the catatonic phenomena haven’t been created yet. The aim: review to therapeutic interventions for catatonic disorders in schizophrenia.Materials and methods: according to the keywords “catatonia treatment”, “catatonia therapy”, publications found in the Scopus, PubMed, Cochrane Library, eLibrary databases were selected and analyzed.Results: historical background, illustrating the development of catatonia treatment methods, is given; the results of the last decades scientific studies of catatonia’s treatment and preliminary results of own study, devoted to the effectiveness of diazepam and cariprazine in relieving catatonia manifestations are presented. Based on the studies’ results, presented in the review, it can be concluded that the most common modern method of treating catatonic disorders is the use of benzodiazepines, however, in some cases, the use of antipsychotics is also advisable. Electroconvulsive therapy (ECT) remains an important treatment for catatonic phenomena. There are also isolated clinical cases of successful testing of both: other pharmacological groups (antidepressants, dopaminergic and anticholinergic drugs, normothymic drugs, etc.) and non-drug interventions (transcranial magnetic stimulation — TMS) presented in modern research data.Conclusion: the effectiveness of benzodiazepines in catatonia, associated with schizophrenia and schizophrenia spectrum disorders (SSD), remains controversial according to modern authors’ opinion. In turn, among antipsychotics, antipsychotics of the second and third generation seem to be safe for the treatment of psychomotor symptoms. In accordance with the results of our own study, catatonia in the structure of schizophrenia and SSD is heterogeneous and, depending on the psychopathological structure of catatonic disorders, a different reaction of psychomotor symptoms to therapeutic intervention was observed.

show abstract

Short-Term Treatment of Catatonia With Amantadine in Schizophrenia and Schizoaffective Disorder

Cited by 11 publications

References 15 publications

Systematic review of catatonia treatment

Systematic review of catatonia treatment

Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence

Therapy of Catatonia in Schizophrenia and Schizophrenia Spectrum Disorders

Contact Info

Product

Resources

About